Humoral theory of transplantation: Some hot topics

British Medical Bulletin

Volumn 105, Issue 1, 2013, Pages 139-155

  Cai, Junchao ^a   Qing, Xin ^b   Tan, Jianming ^c   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c FUZHOU GENERAL HOSPITAL   (China)

Author keywords

alloantibody; antibody mediated rejection; ASKP1240; autoantibody; belimumab; blinatumomab; bortezomib; C1 inhibitor; c4d; dacetuzumab; eculizumab; HLA antibody; rituximab

Indexed keywords

ANGIOTENSIN II TYPE I RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIBODY; ANTICOAGULANT AGENT; ASKP 1240; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD40 ANTIGEN; COLLAGEN TYPE 5; COMPLEMENT COMPONENT C1S INHIBITOR; DACETUZUMAB; DONOR SPECIFIC ANTIBODY; ECULIZUMAB; GALIXIMAB; GLUCOCORTICOID; HUMORAL ANTIBODY; IMGN 529; LUMILIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VIMENTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTIBODY; BIOLOGICAL MARKER; COLLAGEN TYPE 5 ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 5; MYOSIN; NUCLEOLIN; OFATUMUMAB; TUBULIN; VELTUZUMAB; VIMENTIN ANTIBODY;

ALLOGRAFT INJURY; ANTIBODY MEDIATED REJECTION; ANTIBODY MEDIAYED REJECTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL RESEARCH; DATA BASE; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; TISSUE INJURY; ANTIBODY PRODUCTION; GRAFT RECIPIENT; HUMORAL IMMUNITY; IMMUNOADSORPTION; NONHUMAN; ORGAN DONOR; PLASMAPHERESIS; TRANSPLANTATION;

ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; BORONIC ACIDS; COMPLEMENT C4B; GRAFT REJECTION; HUMANS; ISOANTIBODIES; PEPTIDE FRAGMENTS; PYRAZINES; TRANSPLANTATION;

EID: 84876232886     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/lds037     Document Type: Article

References (62)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-9.
2. Cai J, Terasaki PI. Human leukocyte antigen antibodies for monitoring transplant patients. Surg Today 2005;35:605-12.
3. Pei R, Lee JH, Shih NJ et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003;75:43-9.
4. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003;3:665-73.
5. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005;17:541-5.
6. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008;86:377-83.
7. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-37.
8. Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002;74:1192-4.
9. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438-43.
10. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009;87:1505-13.
11. Bohmig GA, Wahrmann M, Saemann MD. Detecting adaptive immunity: applications in transplantation monitoring. Mol Diagn Ther 2010;14:1-11.
12. Sawitzki B, Schlickeiser S, Reinke P et al. Monitoring tolerance and rejection in organ transplant recipients. Biomarkers 2011;16(Suppl. 1):S42-50.
13. Fukami N, Ramachandran S, Saini D et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009;182:309-18.
14. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010;15:16-20.
15. Paul LC, Muralidharan J, Muzaffar SA et al. Antibodies against mesangial cells and their secretory products in chronic renal allograft rejection in the rat. Am J Pathol 1998;152: 1209-23.
16. Joosten SA, van Ham V, Borrias MC et al. Antibodies against mesangial cells in a rat model of chronic renal allograft rejection. Nephrol Dialysis Transplant 2005;20:692-8.
17. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352:558-69.
18. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006;17:889-99.
19. Opelz G, Zeier M, Laux G et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006;17:3257-62.
20. Jurcevic S, Ainsworth ME, Pomerance A et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71:886-92.
21. Carter V, Shenton BK, Jaques B et al. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proceed 2005;37:654-7.
22. Kelishadi SS, Azimzadeh AM, Zhang T et al. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest 2010;120: 1275-84.
23. Burlingham WJ, Love RB, Jankowska-Gan E et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007;117:3498-506.
24. Iwata T, Philipovskiy A, Fisher AJ et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008;181:5738-47.
25. Nath DS, Ilias Basha H, Tiriveedhi V et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibodymediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010;29: 1277-85.
26. Goers TA, Ramachandran S, Aloush A et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008;180:4487-94.
27. Qin Z, Lavingia B, Zou Y et al. Antibodies against nucleolin in recipients of organ transplants. Transplantation 2011;92:829-35.
28. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005;66:334-42.
29. Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for posttransplant lymphoproliferative disorders. Lancet 1998;352:1285.
30. Aranda JM Jr, Scornik JC, Normann SJ et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002;73:907-10.
31. Garrett HE Jr, Groshart K, Duvall-Seaman D et al. Treatment of humoral rejection with rituximab. Ann Thorac Surg 2002;74:1240-2.
32. Becker YT, Becker BN, Pirsch JD et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001.
33. Vianna RM, Mangus RS, Fridell JA et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008;85: 1290-3.
34. Tyden G, Genberg H, Tollemar J et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87: 1325-9.
35. Takagi T, Ishida H, Shirakawa H et al. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010;89:1466-70.
36. Fuchinoue S, Ishii Y, Sawada T et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011;91:853-7.
37. Kohei N, Hirai T, Omoto K et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012;12:469-76.
38. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibodyand cell-mediated acute rejection. Transplantation 2008;86:1754-61.
39. Diwan TS, Raghavaiah S, Burns JM et al. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011;91:536-41.
40. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-9.
41. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010;10:681-6.
42. Woodle ES, Alloway RR, Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 2011;16:434-8.
43. Stohl W, Hiepe F, Latinis KM et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
44. Manzi S, Sanchez-Guerrero J, Merrill JT et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
45. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
46. Oura T, Yamashita K, Suzuki T et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am J Transplant 2012;12:1740-54.
47. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5: 572-7.
48. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-13.
49. Biglarnia AR, Nilsson B, Nilsson T et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011;24:e61-6.
50. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993;56:1171-6.
51. Matsunami K, Miyagawa S, Yamada M et al. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection. Transplantation 2000;69:749-55.
52. Poirier N, Blancho G. Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo- and xenoantibodies. Transplant Proceed 2008;40:581-3.
53. Tillou X, Poirier N, Le Bas-Bernardet S et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010;78:152-9.
54. Roelen DL, Doxiadis II, Claas FH. Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. Transpl Int 2012;25:604-10.
55. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007;7:408-15.
56. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012;93:751-6.
57. Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc) 2009;45:521-32.
58. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-23.
59. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-71.
60. Vega J, Goecke H, Carrasco A et al. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate. Clin Experiment Nephrol 2011;15:308-11.
61. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011;75:271-8.
62. Xu X, Shi B, Cai M et al. A retrospective study of plasma cell infiltrates in explanted renal allografts. Transplant Proceed 2008;40:1366-70.